Trial · NCT07325201
Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
NCT07325201, Phase 2, Not yet recruiting, HealthPartners Institute
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring. Trials, record NCT07325201. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07325201
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Mitigating DKA in Type 1 Diabetes for Safe Use of SGLT Inhibitors Using Dual Continuous Ketone and Glucose Monitoring.
- NCT number
- NCT07325201
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 80 participants, estimated
- Lead sponsor
- HealthPartners Institute
- Conditions
- Type 1 Diabetes Mellitus, Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), Chronic Kidney Disease, Diabetic Ketoacidosis, Ketones
- Interventions
- Sotagliflozin initiation
- First posted
- 2026-01-08
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes30
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in time in ketone range >1.5/mmol/L | 3 months, 6 months, 9 months | |
| Primary | Number of episodes of diabetic ketoacidosis (DKA) | 6 months, 9 months | |
| Secondary | Change in mean ketone level | 3 months, 6 months, 9 months | |
| Secondary | Highest ketone level in time period | 6 months, 9 months | |
| Secondary | Number of severe hypoglycemia episodes | 3 months, 6 months | |
| Secondary | Number of episodes (>=15 minutes) at >1.5 mmol/L | 6 months, 9 months | |
| Secondary | Number of prolonged episodes (>=2 hours) at >1.5 mmol/L | 6 months, 9 months | |
| Secondary | Change in time in ketone level >3.0/mmol/L | 3 months, 6 months, 9 months | |
| Secondary | Number of episodes (>=15 minutes) at >3.0 mmol/L | 6 months, 9 months | |
| Secondary | Number of prolonged episodes (>=2 hours) at >3.0 mmol/L | 6 months, 9 months |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers30
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01DK143379 | Mitigating Diabetic Ketoacidosis in People with T1D and Chronic Kidney Disease on an SGLT1&2 Inhibitor: Ketosis Risk Factor Determination and Incorporation into an Enhanced Glucose Ketone Report | BERGENSTAL, RICHARD MAURITZ | HEALTHPARTNERS INSTITUTE | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07325201
GET https://conductscience.org/api/trials/v1/NCT07325201/registered?page=2